Crizotinib: New Standard for ALK+ Myofibroblastic Tumor

With 100% disease control rates in patients with ALK+ inflammatory myofibroblastic tumor — a very rare type of soft tissue sarcoma — crizotinib should be the standard of care, say experts. Medscape Medical News